Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials

J Am Coll Cardiol.

Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr; PREVAIL and PROTECT AF Investigators

doi: 10.1016/j.jacc.2017.10.021.

Atrial Fibrillation

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

J Am Coll Cardiol.

Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, Poloczek M, Stasek J, Haman L, Branny M, Chovancik J, Cervinka P, Holy J, Kovarnik T, Zemanek D, Havranek S, Vancura V, Opatrny J, Peichl P, Tousek P, Lekesova V, Jarkovsky J, Novackova M, Benesova K, Widimsky P, Reddy VY, PRAGUE-17 Trial Investigators.

doi: 10.1016/j.jacc.2020.04.067.

Atrial Fibrillation

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology

Circ Arrhythm Electrophysiol.

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Mazzone P, Foley D, Grygier M, Sievert H, De Potter T, Vireca E, Stein K, Bergmann MW, following investigators and institutions participated in the EWOLUTION study

doi: 10.1161/CIRCEP.

Atrial FibrillationMyocardial InfarctionThrombosis and Stroke

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF

Int J Cardiol.

Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP

doi: 10.1016/j.ijcard.2017.06.110.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients

JACC: Clinical Electrophysiology.

Kubo S, Mizutani Y, Meemook K, Nakajima Y, Hussaini A, Kar S

doi: 10.1016/j.jacep.2017.05.006.

Atrial Fibrillation

"AF HeartTeam" Guided Indication for Stand-alone Thoracoscopic Left Atrial Ablation and Left Atrial Appendage Closure

J Atr Fibrillation.

Salzberg SP, van Boven WJ, Wyss C, Hürlimann D, Reho I, Zerm T, Noll G, Emmert MY, Corti R, Grünenfelder J

doi: 10.4022/jafib.2039.

Atrial FibrillationThrombosis and Stroke

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients

Thromb Haemost.

Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GY

doi: 10.1160/

Further Publications

Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17

J Am Coll Cardiol

Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, Poloczek M, Stasek J, Haman L, Branny M, Chovancik J, Cervinka P, Holy J, Kovarnik T, Zemanek D, Havranek S, Vancura V, Peichl P, Tousek P, Lekesova V, Jarkovsky J, Novackova M, Benesova K, Widimsky P, Reddy VY, PRAGUE-17 Trial Investigators.

doi: 10.1016/j.jacc.2021.10.023

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial

JAMA Cardiol.

Cowper PA, Sheng S, Lopes RD1, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJ, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB

doi: 10.1001/jamacardio.

Related content

5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF

Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients

"AF HeartTeam" Guided Indication for Stand-alone Thoracoscopic Left Atrial Ablation and Left Atrial Appendage Closure

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients

Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial